A new paclitaxel prodrug for use in ADEPT strategy

Organic and Biomolecular Chemistry

Volumn 1, Issue 19, 2003, Pages 3343-3352

  Bouvier, Emmanuel ^a   Thirot, Sylvie ^a   Schmidt, Frédéric ^a   Monneret, Claude ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; DERIVATIVES; DRUG PRODUCTS; SUGAR (SUCROSE);

PACLITAXEL PRODRUG;

POLYAMIDES;

EID: 0142126227     PISSN: 14770520     EISSN: None     Source Type: Journal    
DOI: 10.1039/b306236h     Document Type: Article

References (56)

1. M. von Mehren and L. Weiner, Curr. Opin. Oncol., 1996, 8, 493-498.
2. A. Scott and S. Welt, Curr. Opin. Oncol., 1997, 9, 717-722.
3. P. Carter, Nat. Rev. Cancer, 2001, 1, 118-129.
4. L. Sorbera and X. Rabasseda, Drugs Future, 1998, 23, 1078-1082.
5. K. Bagshawe, Br. J. Cancer, 1987, 56, 531-532.
6. K. Bagshawe, Drug Dev. Res., 1995, 34, 220-230.
7. R. Melton, R. Knox and T. Connors, Drugs Future, 1996, 21, 167-181.
8. I. Niculescu-Duvaz and C. Springer, Curr. Med. Chem., 1995, 2, 687-706.
9. W. Denny and W. Wilson, J. Pharm. Pharmacol., 1998, 50, 387-394.
10. P. Senter and K. Hellstrom, Bioconjugate Chem., 1993, 4, 3-9.
11. K. Bagshawe, Clinical Pharmacokinet., 1994, 27, 368-376.
12. K. Bagshawe, Cell Biophys., 1994, 24, 2583-2591.
13. K. Bagshawe, Biochem. Soc. Trans., 1990, 18, 750-752.
14. F. Huennekens, Trends Biotechnol., 1994, 12, 234-239.
15. M. Deonarain and A. Epenetos, Br. J. Cancer, 1994, 70, 786-794.
16. K. Bosslet, J. Czech, G. Seemann, C. Monneret and D. Hoffmann, Cell Biophys., 1994, 24-25, 51-63.
17. J.-C. Jacquesy, J.-P. Gesson, C. Monneret, M. Mondon, B. Renoux, J.-C. Florent, M. Koch, F. Tillequin, H. Sedlacek, M. Gerken, C. Kolar and G. Gaudel, Patent WO 92/19639, 1992.
18. K. Bosslet, J. Czech and D. Hoffmann, Cancer Res., 1994, 54, 2151-2159.
19. K. Bosslet, J. Czech, H. Lorenz, M. Sedlacek, M. Schuermann and G. Seemann, Br. J. Chem., 1992, 65, 234-238.
20. C. Monneret, J.-C. Florent, J.-C. Gesson, J.-C. Jacquesy, F. Tillequin and M. Koch, ACS Symp. Ser., 1995, 574, 78-99.
21. K. Bosslet, J. Czech, P. Lorenz, H. Sedlacek, M. Schuermann and G. Seemann, Br. J. Cancer, 1992, 65, 234-238.
22. K. Bosslet, R. Straub, M. Gerken, H. Petrul, J. Czech, J.-C. Florent, M. Koch, F. Tillequin, F. Schmidt, C. Monneret and J.-P. Gesson, 4. Salzburger Symposium zur Lebensqualität chrinisch Kranker, 1996, Georg Thieme Verlag, Stuttgart-New York, pp. 123-130.
23. K. Bosslet, R. Straub, M. Blumrich, J. Czech, J. M. Gerken, B. Sperker, H. Kroemer, J.-P. Gesson, M. Koch and C. Monneret, Cancer Res., 1998, 58, 1195-1201.
24. T. Murdter, B. Sperker, K. Kivisto, M. McClellan, P. Fritz, G. Friedel, A. Linder, K. Bosslet, H. Toomes, R. Dierkesmann and H. Kroemer, Cancer Res., 1997, 57, 2440-2445.
25. M. Wani, H. Taylor, M. Wall, P. Coggon and A. McPhail, J. Am. Chem. Soc., 1971, 93, 2325-2337.
26. K. Nicolaou, W.-M. Dai and R. Guy, Angew. Chem., Int. Ed. Engl., 1994, 33, 15-44.
27. D. Guénard, F. Guéritte-Voegelein and P. Potier, Acc. Chem. Res., 1993, 26, 160-167.
28. D. Kingston, Trends Biotechnol., 1994, 12, 222-227.
29. W. Slichenmyer and D. Von Hoff, Anti-Cancer Drugs, 1991, 2, 519-530.
30. B. Chabner, Principles & Practice of Oncology Updates, 1991, 5, 1-10.
31. J. Szebeni, F. Muggia and C. Alving, J. Natl. Cancer Inst., 1998, 90, 300-306.
32. A. Whal, F. Guéritte-Voegelein, D. Guénard, M. Le Goff and P. Potier, Tetrahedron, 1992, 48, 6965-6974.
33. M. Hepperle and G. Georg, Drugs Future, 1994, 19, 573-584.
34. R. Greenwald, A. Pendri and D. Bolikal, J. Org. Chem., 1995, 60, 331-336.
35. A. Mathew, M. Mejillano, J. Nath, R. Himes and V. Stella, J. Med. Chem., 1992, 35, 145-151.
36. H. Deutsch, J. Glinski, M. Hernandez, R. Haugwitz, V. Narayanan, M. Suffness and L. Zalkow, J. Med. Chem., 1989, 32, 788-792.
37. A. Pendri, C. Conover and R. Greenwald, Anti-Cancer Drug Des., 1998, 13, 387-395.
38. N. Harada, K. Ozaki, T. Yamaguchi, H. Arakawa, A. Ando, K. Oda, N. Nakanishi, M. Ohashi, T. Hashiyama and K. Tsujihara, Heterocycles, 1997, 46, 241-258.
39. Z. Zhao, D. Kingston and A. Crosswell, J. Nat. Prod., 1991, 54, 1607-1611.
40. M. Rodrigues, P. Carter, C. Wirth, S. Mullins, A. Lee and B. Blackburn, Chem. Biol., 1995, 2, 223-227.
41. K. Bagshawe and R. Begent, Adv. Drug Delivery Rev., 1996, 22, 365-367.
42. D. de Bont, R. Leenders, H. Haisma, I. van der Meulen-Muileman and H. Scheeren, Bioorg. Med. Chem., 1997, 5, 405-414.
43. F. de Groot, L. van Berkom and H. Scheeren, J. Med. Chem., 2000, 43, 3093-3102.
44. E. Damen, T. Nevalainen, T. vandenBergh, F. de Groot and H. Scheeren, Bioorg. Med. Chem, 2002, 10, 71-77.
45. F. Schmidt, I. Ungureanu, I. R. Duval, A. Pompon and C. Monneret, Eur. J. Org. Chem., 2001, 2129-2134.
46. S. Jain, W. Drendel, Z.-W. Chen, F. Matthews, W. Sly and J. Grubb, Nat. Struct. Biol., 1996, 3, 375-381.
47. R. Lougerstay-Madec, J.-C. Florent, C. Monneret, F. Nemati and M.-F. Poupon, Anti-Cancer Drug Des., 1998, 13, 995-1007.
48. F. de Groot, W. Loos, R. Koekoek, L. van Berkom, L. Busscher, A. Seelen, C. Albrecht and P. de Bruijn, J. Org. Chem., 2001, 66, 8815-8830.
49. J.-C. Florent, X. Dong, G. Gaudel, S. Mitaku, C. Monneret, J.-P. Gesson, J.-C. Jacquesy, M. Mondon, B. Renoux, S. Andrianomenjanahary, S. Michel, M. Koch, F. Tillequin, M. Gerken, J. Czech, R. Straub and K. Bosslet, J. Med. Chem., 1998, 41, 3572-3581.
50. S. Chen, S. Huang, J. Wei and V. Farina, Tetrahedron., 1993, 49, 2805-2828.
51. G. Samaranayake, N. Magri, C. Jitrangsri and D. Kingston, J. Org. Chem., 1991, 56, 5114-5119.
52. M. Tanaka, M. Okita and I. Yamatsu, Carbohydr. Res., 1993, 241, 81-88.
53. N. Mignet, C. Chaix, B. Rayner and J.-L. Imbach, Carbohydr. Res., 1997, 303(1), 17-24.
54. S. Higashibayashi, K. Shinko, T. Ishizu, K. Hashimoto, H. Shirahama and M. Nakata, Synlett, 2000, 9, 1306-1308.
55. W. Saari, J. Schwering, P. Lyle, S. Smith and E. Engelhardt, J. Med. Chem., 1990, 33(1), 97-101.
56. S. Desbène, H. Dufat-Trinh, S. Michel, M. Koch, F. Tillequin, G. Fournier, N. Farjaudon and C. Monneret, Anti-Cancer Drug Des., 1998, 13, 955-968.